|
1) TASC Working Group. Management of peripheral arterial disease. J Vasc Surg. 2000; 31(1, Part 2): S1-296
|
|
|
|
2) Hirsch AT, et al. ACC/AHA 2005 Practice Guidelines for the management of patients with peripheral arterial disease (lower extremity, renal, mesenteric, and abdominal aortic): a collaborative report from the American Association for Vascular Surgery/Society for Vascular Surgery, Society for Cardiovascular Angiography and Interventions, Society for Vascular Medicine and Biology, Society of Interventional Radiology, and the ACC/AHA Task Force on Practice Guidelines. Circulation. 2006; 113: e463-654
|
|
|
|
|
3) 日本脈管学会, 編. 下肢閉塞性動脈硬化症の診断・治療指針. 東京: バイオメディスインターナショナル; 2000
|
|
|
|
|
|
4) Norgren L, Hiatt WR (ed). Inter-Society consensus for the management of peripheral arterial disease (TASC II). J Vasc Surg. 2007; 45 Suppl. S: S1-67
|
|
|
|
|
|
5) TASC Working Group/日本脈管学会, 訳. 下肢閉塞性動脈硬化症の診断・治療指針(日本脈管学会, 編. 監訳: 重松 宏). 東京: メディカルトリビューン社; 2007. p. 1-109
|
|
|
|
|
|
6) Regensteiner JG, Ware JEJr., McCarthy WJ, et al. Effect of cilostazol on treadmill walking, community-based walking ability, and health-related quality of life in patients with intermittent claudication due to peripheral arterial disease: meta-analysis of six randomized controlled trials. J Am Geriatr Soc. 2002; 50: 1939-46
|
|
|
|
|
|
7) Dormandy JA, Belcher G, Bross P, et al. A prospective study of 713 below-knee amputations for ischemia and the effect of a prostacyclin analogue on healing. Br J Surg. 1994; 81: 33-7
|
|
|
|
|